

Press Release

Lille, 29th April 2021

4Moving Biotech announces a closing of €2M investment to implement 4P004 phase 1 clinical trial on Osteoarthritis patients

Lille, France, 29th April 2021 – 4Moving Biotech, a French biotech start-up company, announces that it has closed a €2M investment agreement with 4P-Pharma, SATT Lutech, French Tech Seed and business angels. 4Moving Biotech is an asset centric company focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD). 4Moving Biotech intends to use the proceeds to initiate a phase I clinical trial on people suffering from osteoarthritis.

A closing of €2M

4Moving Biotech announces that it has closed a €2M investment agreement with 4P-Pharma, SATT Lutech, French Tech Seed and business angels. For its first round of funding, 4Moving Biotech benefited from the private investment of 4P-Pharma and SATT Lutech for €1.25M in equity, reinforced by the support of private business angels and French Tech Seed Fund (managed by the French Public Investment Bank, Bpifrance) for €750K in convertible bonds.

Osteoarthritis, an urgent unmet medical need

Osteoarthritis (OA) is a chronic degenerative disease of the joints, it is one of the most common painful diseases and the leading cause of disability among people over 50. Worldwide, over 300 million people are affected, representing 15% of the adult population. Nearly one out of two adults will suffer from knee or hip osteoarthritis in their lifetime. Due to the aging population and rising obesity rate, the disease prevalence is sharply rising.

So far, no disease-modifying OA drugs changing the course of the disease have been approved by US or European medicines agencies, patients rely on poorly effective symptomatic treatments such as analgesics and anti-inflammatory drugs to ease OA-induced pain. In the final stages when the symptoms worsen, invasive total joint replacement surgery becomes inevitable. OA is therefore a pressing unmet need.

In addition, OA imposes a heavy economic burden on patients and health care systems. In 2010, in France, direct medical costs exceeded €3.5Bn, and costs in the US were estimated up to \$200Bn annually.

4P004, a promising DMOAD

Since 2015, 4P-Pharma, Prof. Francis Berenbaum's Sorbonne University-INSERM laboratory and SATT Lutech have joined their expertise to develop 4P004.

The innovation originates from the laboratory of Prof. Berenbaum and has been selected among 300 scouted technologies by 4P-Pharma. Today, 4P004 is transferred to 4Moving Biotech, an asset

centric company and subsidiary of 4P-Pharma, directed by Revital Rattenbach, PhD, MBA, as Chairwoman and Francis Berenbaum as Chief Executive Officer/Chief Medical Officer.

This successful public-private collaboration has demonstrated that this innovation is a promising DMOAD. 4P004 is a GLP1 analog repurposed drug formulated for intra-articular administration. It is characterized by a unique triple effect: anti-inflammatory, analgesic and cartilage regeneration, therefore providing a long-term solution for people suffering from OA.

After a thorough technical value validation with a large array of preclinical model studies, as well as veterinary pilot clinical phase on spontaneous OA in dogs, 4P004 is now ready to move towards human clinical phases on OA patients.

“The incorporation and development of 4Moving Biotech is the proof of the relevancy of 4P-Pharma business model: bringing to patient the best innovations from academic scientists, in a relatively short time and with limited risks”, says Revital Rattenbach, Chairwoman of 4Moving Biotech and 4P-Pharma. “I am delighted to have achieved this first round of financing for 4Moving Biotech thanks to the trust of our investors and partners of several years.”

“This fundraising gives us an extraordinary opportunity to conduct our first clinical trial in women and men suffering from OA with 4P004”, adds Francis Berenbaum, CEO/CMO of 4Moving Biotech, Head of rheumatology department at Saint-Antoine Hospital (AP-HP), and Professor at Sorbonne University (Paris, France). “This opens up a unique opportunity for us to bring to market in the short term the first disease-modifying treatment for osteoarthritis.”

About 4P004

4P004 is a disease modifying drug for the treatment of Osteoarthritis (OA), developed by 4P-Pharma and 4Moving Biotech. It is an already approved incretin mimetic (a Glucagon-Like Peptide-1 receptor agonist) now formulated for intra-articular administration. OA is a chronic degenerative disease characterized by chronic joint pain and functional impairment, affecting 15% of the worldwide adult population. 4P004 has the potential to stop and reverse the course of the disease improving patient's quality of life through its unique triple effect: anti-inflammatory, analgesic and cartilage regeneration, thus qualifying as a Disease Modifying OA Drug. Protected by two international patents, it has undergone extensive preclinical validation and will move towards clinical phases in 2021.

About 4Moving Biotech

4Moving Biotech is a biotech start-up company focusing on the development of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD). It addresses the high unmet medical need for a curative treatment against Osteoarthritis (OA), a chronic degenerative joint disease.

4Moving Biotech was established in July 2020 and is a majority-owned subsidiary of 4P-Pharma. The company is headquartered at the Institut Pasteur de Lille (France).

4Moving Biotech is headed by Revital Rattenbach, PhD, MBA, founder and chairwoman of 4P-Pharma, as Chairwoman, and Prof. Francis Berenbaum, Head of rheumatology department at St-Antoine's hospital (AP-HP) in Paris, as CEO/CMO.

<https://4p-pharma.com/our-pipeline/pipeline-inflammation/>

<https://www.linkedin.com/company/4moving-biotech/>

@4Moving_Biotech

About 4P-Pharma

4P-Pharma is a French clinical-stage biotechnology company, located at the Institut Pasteur de Lille, specialized in the sourcing and acceleration of early-stage therapeutic molecules addressing unmet medical needs. 4P-Pharma aims to detect the most promising innovations from partners (i.e. academic institutions, biotech companies and TTOs) and perform in-house technological due-diligence applying stringent industry criteria. 4P-Pharma gathers all the relevant actors from the clinic, drug development, finance and business fields to move technologies through developmental decision to bring innovations to clinical phases. Since 4P-Pharma's foundation in 2014, more than 300 molecules have been pre-evaluated, technological due diligence has been carried out on 18 of them. Two are now incorporated in clinical-stage asset centric companies owned by 4P-Pharma.

<https://4p-pharma.com/>
www.linkedin.com/company/4p-pharma/
@4P_Pharma

About SATT Lutech

SATT LUTECH is a private technology transfer company with exclusive rights to source, protect, develop and commercialize scientific findings stemming from the research laboratories of its partners and shareholders (Sorbonne Université, CNRS, Université de Technologie de Compiègne, Muséum National d'Histoire Naturelle, Université Panthéon-Assas, Ecole Nationale Supérieure de Création Industrielle and BPI France). SATT Lutech aims at facilitating the transfer of early-stage innovations with a real potential to improve life quality, transform industries, and create tremendous social & economic value, from the lab to successful products and services, by investing in the development of convincing proof of concept and prototypes. SATT Lutech is partnering with operating companies and investors, at any development stage, through co-development programs, licensing or startup creation, in the field of healthcare, chemistry, ICT, engineering and human & social sciences.

<https://www.sattlutech.com/>
<https://www.linkedin.com/company/satt-lutech/>
@SATTLutech

About French Tech Seed Fund and Bpifrance

With 400 million euros and managed by Bpifrance, the French Tech Seed fund is intended to give leverage to private investment in technology companies under 3 years of age. It operates in a logic of co-investment. From the Future Investment Program, the fund operates through certified prescribers who identify and qualify future technology nuggets and work in coordination with private investors.

Bpifrance finances companies - at every stage of their development - with credit, guarantees and equity. Bpifrance supports them in their innovation projects and internationally. Bpifrance also ensures their export activity through a wide range of products. Consulting, university, networking and acceleration programs for start-ups, SMEs and ETIs are also part of the offer proposed to entrepreneurs. Thanks to Bpifrance and its 50 regional offices, entrepreneurs benefit from a close, unique and efficient contact to help them face their challenges.

<https://lafrenchtech.com/fr/> - <https://www.bpifrance.fr/>
<https://www.linkedin.com/company/la-french-tech/> - <https://www.linkedin.com/company/bpifrance/>
@LaFrenchTech - @Bpifrance - @BpifrancePresse

■ **4Moving Biotech - press contact**
■ **Roselina Lam**, Business Development and Licensing Manager
■ E-mail: contact@4moving-biotech.com
■